Highlights
About
Minimally Invasive Surgical Device for Glaucoma Treatment
Sanoculis offers a new alternative surgical procedure for treating glaucoma. Its Minimally Invasive Micro Sclerostomy (MIMS) solution consists of a single-patient-use sterile tool and a multi-use external machine. In the course of the surgery, a sclero-corneal drainage channel is created to reduce intraocular pressure. MIMS is a microfluidic full-thickness procedure developed as an advanced laser sclerostomy. The technique uses a cutting and drilling device to reduce trauma to the surrounding tissue, minimizing scar tissue formation and allowing for a long-lasting filtering bleb. The MIMS channel ensures a controlled fluid flow with minor complications. In March 2017, Sanoculis was granted CE marking for its MIMS device and procedure.
Identity
| Name | Sanoculis |
|---|---|
| Slug | sanoculis |
| Type / kind | startup |
| Crunchbase ID | sanoculis |
| Source _id | agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgJ6Tj78JDA |
Status
| Status | active |
|---|---|
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ region/district | Center District |
| HQ city | Kiryat Ono |
| HQ address | Landau Street 10, Kiryat Ono, Israel |
Web & social
| Website | https://sanoculis.com |
|---|---|
| https://www.linkedin.com/company/68842608 | |
| YouTube | https://www.youtube.com/channel/UCT1KBtmpyTEvqDlwL5BG6mQ |
Classifications
Funding
| Total raised | $18.5M |
|---|---|
| Current stage | Series C |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}